Comparative Pharmacology
Head-to-head clinical analysis: DIPHENOXYLATE HYDROCHLORIDE W ATROPINE SULFATE versus MOTOFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENOXYLATE HYDROCHLORIDE W ATROPINE SULFATE versus MOTOFEN.
DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE vs MOTOFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenoxylate acts as an opioid agonist on mu-opioid receptors in the gastrointestinal tract, reducing peristalsis and increasing intestinal transit time. Atropine sulfate is added at subtherapeutic doses to deter abuse by causing unpleasant anticholinergic effects at high doses.
Combination of diphenoxylate (opioid agonist) and atropine (anticholinergic). Diphenoxylate acts on μ-opioid receptors in the gut to slow peristalsis and reduce fluid secretion; atropine is added to discourage abuse by causing unpleasant anticholinergic effects at high doses.
2.5-5 mg (diphenoxylate) orally 4 times daily until diarrhea controlled; maximum 20 mg/day (diphenoxylate).
1 to 2 tablets orally every 6 hours as needed, not to exceed 8 tablets per day.
None Documented
None Documented
Diphenoxylate: terminal half-life of 2.9-5.8 hours (active metabolite difenoxin: 12-14 hours). Atropine: terminal half-life of 2-4 hours. Clinical context: The long half-life of difenoxin contributes to sustained antidiarrheal effect.
Terminal elimination half-life: 20-24 hours; clinical context: once-daily dosing recommended
Diphenoxylate is excreted primarily in feces (via biliary elimination) as the active metabolite difenoxin and its conjugates; approximately 14% is excreted renally as unchanged drug and metabolites. Atropine is excreted renally (30-50% unchanged) and partially in feces.
Renal: ~60%; Fecal/Biliary: ~40%
Category C
Category C
Antidiarrheal
Antidiarrheal